The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2016Cognitive Behavioral Therapy for Anxiety Disorders in Parkinson's Disease
Study Rationale:
Anxiety disorders occur in up to 35 percent of people with Parkinson's disease and can have a negative impact on gait, involuntary movements, motor fluctuations and quality of life... -
Research Grant, 2016Inhibition of Striatal-enriched Phosphate (STEP) to Improve Parkinson-related Cognitive Dysfunction
Promising Outcomes of Original Grant:
Our original funded project was designed to examine absorption and distribution of the STEP (Striatal-Enriched Phosphatase), a protein associated with several... -
Improved Biomarkers and Clinical Outcome Measures, 2018Cognitive-driven Activities of Daily Living Impairment as a Predictor for Parkinson's Disease Dementia
Study Rationale:
Mild cognitive impairment in Parkinson's disease (PD-MCI) is the highest risk factor for Parkinson's disease dementia (PDD). The core feature for differentiating PDD from PD-MCI is... -
Fall 2025 RFP: Data Advice To Action, 2026Identifying Blood-Based Proteomic Biomarkers of Cognitive Decline and its Pathological Heterogeneity in PD and DLB
Study Rationale:
Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB) both feature debilitating cognitive decline without reliably effective therapies. This dearth of...
-
Biosample Use Program, 2020Adaptive Immune Markers for Predicting Cognitive Decline in Parkinson’s Disease
Study Rationale:
For reasons not well understood, people with Parkinson's disease are at risk for developing dementia, a decline in memory, thinking and/or language abilities severe enough to... -
Research Grant, 2020Evaluation of ANAVEX2-73 (blarcamesine) in Participants with Parkinson’s Disease
Study Rationale:
We are testing ANAVEX2-73 (also known as blarcamesine), which previous research has shown helps improve behaviors as well as normalizes biochemical changes in a Parkinson’s...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.